RE:University of Calgary “Promising” results on a cureThanks stockwatcher. Neuronal hyperactivity and its AD cycle haven't been discussed publicly by Promis so far as I'm aware, but it's a great question. In 2015 the relevant situation was summarized in a 3rd party abstract as
" AβO binding triggers a redistribution of critical synaptic proteins and induces hyperactivity in metabotropic and ionotropic glutamate receptors. This leads to Ca(2+) overload and instigates major facets of AD neuropathology, including tau hyperphosphorylation, insulin resistance, oxidative stress, and synapse loss. Because different species of AβOs have been identified, a remaining question is which oligomer is the major pathogenic culprit. " https://pubmed.ncbi.nlm.nih.gov/25604547/ So we're invested in the "which oligomer" side of the cycle while Dr. Chen in Calgary is working on the other side, neuronal hyperactivity.